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Background/aim: Besides some genetic explanations of the native course of ulcerative colitis (UC), the most attributable factors are
pathogenic bacterial agents. There are some conflicting data about the relationship between Helicobacter pylori and the rate of UC in the
literature. Therefore, we aimed to investigate the rate of H. pylori in UC patients.
Materials and methods: Forty-nine individuals diagnosed with UC who had undergone upper gastrointestinal tract endoscopy for
different reasons were included in the study. The presence of H. pylori in the stomach was checked by histopathological examination.
Results: H. pylori positivity was present in 57.1% of patients with UC. Interestingly, H. pylori positivity was lower (11.1%) in pancolitis
patients compared to those presenting with more limited illnesses. There were no relationships among the severity of the underlying
disease, medication already used, and H. pylori positivity rate.
Conclusion: The extension of UC is important for the positivity rate of H. pylori. It could not be determined whether the low positivity
of H. pylori in extended UC cases was due to immunosuppressive drugs or to the UC itself.
Key words: Ulcerative colitis, Helicobacter pylori, immunosuppressive drugs

1. Introduction
Ulcerative colitis (UC), characterized by permanent
mucosal inflammatory processes, presents with remission
and activating periods (1). Although some environmental
and genetic causes are attributed to UC progression, the
exact cause of the disease is still unclear (1,2). In the recent
years, investigators have focused on some pathogens as
causes of UC (3,4).
Helicobacter pylori, a pathogen related to chronic
gastritis and peptic ulcers, is colonized mainly in the
antrum, protecting itself from hyperacidity (5,6). Almost
half of the underdeveloped populations are infected by H.
pylori. Apart from the gastrointestinal system disorders, H.
pylori is also found to be related to several skin diseases,
autoimmune disorders, and iron deficiency (7,8). The
association between H. pylori and UC is controversial.
Some researchers reported that incidence of H. pylori is
lower in UC patients than in healthy populations (9–12).
Possible causes of this low rate of H. pylori in UC patients
are the immunopathological characteristics of UC and the
medications used in UC, such as 5-aminosalicylic acid (5ASA) and antibiotics (9–12).
* Correspondence: drakifa@yahoo.com
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We investigated the incidence of H. pylori in
individuals with UC and determined the impact of several
characteristics of UC, including extent and severity of UC,
on the incidence of H. pylori.
2. Materials and methods
Patients who were diagnosed with colitis and admitted to
the outpatient gastroenterology clinic of Numune Training
and Research Hospital were included in the study.
Specifically, 49 patients with UC who had undergone
upper gastrointestinal endoscopy with various indications
were included in the study. The presence of H. pylori
was assessed by taking one biopsy from the antrum in
each patient. Patients using antacids or antibiotics in the
previous 2 months or who had previously undergone
H. pylori eradication treatment were excluded from the
study. Prior to the study, all UC patients were required to
provide an informed consent form and the study design
was submitted to local ethics committee for approval.
The density of the colonization of H. pylori was assessed
by using Sydney classification (13). The demographic data
of the patients in each group were obtained from the
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hospital records. The UC patients were also divided into 4
groups according to the extension of the underlying disease
(distal type, left-sided type, extensive type, and pancolitis).
The clinical activity of UC was scored by the Truelove and
Witts criteria (14) and was divided into 3 groups (mild,
intermediate, and severe). The endoscopic activity was
assessed using the Rachmilewitz scoring system (15).
Statistical analyses were performed with SPSS 15.0
for Windows. The normal distribution of continuous
variables was evaluated by histogram and one-sample
Kolmogorov–Smirnov test. P > 0.05 was considered to
be normal distribution. Normally distributed continuous
variables were expressed as mean ± standard deviation,
continuous variables that were not normally distributed as
median (minimum maximum), and nominal variables as
number and percentage. The differences between normally
distributed independent variables were calculated by
independent samples t-test; the Mann–Whitney U test was
used when the distribution did not appear to be normal
and the Kruskal–Wallis test was used in the comparison
of more than 3 groups. The relationship among nominal
values was determined by the Pearson chi-square test and
Fisher exact test. All calculations were 2-tailed and P <
0.05 was considered to be significant.

3. Results
Forty-nine patients were included in the study. The mean
age of the individuals was 40.5 ± 10.3 years and 62.5% of
them were male.
Overall positivity of H. pylori in gastric mucosa was
57.1% in the UC patients. Although baseline features of
the patients such as mean age, sex distribution, history
of alcohol use and smoking, and severity of underlying
UC were similar in each group, the patients presenting
with pancolitis had the lowest rate of H. pylori (11.1%)
among UC patients (P = 0.005) (Table 1). On the other
hand, the density of H. pylori colonization according to the
pathological examination was found to be similar in each
group (data not shown).
The UC patients were categorized according to
the severity of disease. All groups were similar when
compared according to baseline characteristics (mean
age, sex distribution, history of alcohol use and smoking,
and positivity of H. pylori and its density of colonization)
(Table 2).
Most of the patients were only under the 5-ASA
treatment (77.6%), and the rest were under 5-ASA
treatment and immunomodulatory medication. Although
the positivity of H. pylori in the combination group was

Table 1. The comparison of data based on the extension of UC.
Distal (n = 27)

Left-sided (n = 9)

Extensive (n = 4)

Pancolitis (n = 9)

P-value*

Age, mean ± SD

41.07 ± 10.53

36.88 ± 11.54

47.25 ± 11.44

39.66 ± 7.46

0.178

Male/female, n

18/9

6/3

4/0

3/6

0.113

Alcohol use, n (%)

4 (14.8%)

1 (11.1%)

0 (0%)

1 (11.1%)

0.862

Smoking, n (%)

8 (29.6%)

2 (22.2%)

0 (0%)

2 (22.2%)

0.630

Mild severity of UC, n (%)

21 (77.8%)

5 (55.6%)

2 (50.0%)

5 (55.6%)

Positivity of H. pylori, n (%)

18 (66.7%)

7 (77.8%)

2 (50.0%)

1 (11.1%)

0.217
0.015**

*The cutoff value of statistical significance was considered to be <0.05 by using the Kruskal–Wallis test.
**The Mann–Whitney U test, as a post-hoc test, revealed a difference between the pancolitis group and the others, whereas no difference
was found among the others.
Table 2. The comparison of variables according to the severity of UC.
Mild (n = 33)

Intermediate (n = 13)

Severe (n = 3)

P-value*

Age, mean ± SD

42.39 ± 8.73

35.07 ± 12.73

44.00 ± 9.53

0.170

Male/female, n

21/12

8/5

2/1

0.983

Alcohol use, n (%)

4 (12.1%)

1 (7.7%)

1 (33.3%)

0.474

Smoking, n (%)

9 (27.3%)

3 (23.1%)

0 (0%)

0.570

Positivity of H. pylori, n (%)

19 (57.6%)

7 (53.8%)

2 (66.7%)

0.918

*P < 0.05 was considered to be a cutoff value for statistical significance.
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lower than in 5-ASA group (63.2% vs. 36.4%, respectively),
the difference did not reach statistical significance (P =
0.114) (Table 3). The density of H. pylori colonization was
similar in both groups.
Approximately 10% of the UC patients had a history of
surgery related to UC; the H. pylori positivity was 20.0%
in the patients that had a history of surgery, whereas it was
61.4% in patients without surgery (P = 0.150).
4. Discussion
Recent studies have demonstrated that the incidence of
H. pylori is lower in individuals with UC than in healthy
populations (9–11,16). Some studies have indicated that
the rate of H. pylori is lower in the patients prescribed
5-ASA or sulfasalazine (9,10,12,17). With sulfasalazine
therapy for 14 days, there was a mild suppression in
the urea breath test, but eradication of H. pylori was
not observed (6). The inhibiting effect of sulfasalazine
on H. pylori replication was also shown in vitro, but
no bactericidal or bacteriostatic effect was found (9).
Sulfasalazine probably blocked the adhesion of H. pylori
to the gastric mucosa directly over receptors or indirectly
by its antiinflammatory effect (18,19). Some investigators
reported that the rate of H. pylori was lower in UC patients
than in healthy controls, but this was not related to any
drugs used for UC (20). Another hypothesis suggested that,
with aging, both H. pylori rate and the use of sulfasalazine
increase (20).

Although we did not have any UC patients currently
under corticosteroid therapy, the literature revealed no
effect of corticosteroids on the prevalence of H. pylori (17).
However, our results showed that the positivity of H. pylori
was lower in UC patients presenting with pancolitis than
in patients with more limited diseases. On the other hand,
despite not reaching statistical significance, the presence of
H. pylori was found to be lower in patients under 5-ASA
and immunosuppressive treatment than in those with
5-ASA therapy alone. This may be attributed to the higher
rate of immunosuppressive use in extended diseases,
which has a powerful antiinflammatory effect blocking
the ability of H. pylori to adhere to the gastric mucosa in
UC patients presenting with pancolitis. The other possible
explanation of these results is that UC has been thought
to have an independent protective effect against H. pylori
colonization (18,20).
The main restriction of our study is that we did not
include a healthy group to compare with UC patients.
Thus, we did not investigate whether the H. pylori rate
in UC patients is different from that in healthy controls;
we only focused on the assessment of H. pylori rate in UC
patients in terms of underlying medications and extent of
the disease.
In conclusion, our results revealed that the rate of H.
pylori declined with the elongation of the extent of UC
cases; however, it did not differ in terms of severity of UC
and the prescribed medications.

Table 3. The comparison of results according to the medications used for UC.
5-ASA (n = 49)

5-ASA + Immunosuppressive
(n = 40)

P-value*

Age, mean ± SD

40.89 ± 10.68

39.36 ± 9.27

0.640

Male/female, n

25 / 13

6/5

0.464

Alcohol use, n (%)

5 (13.2%)

1 (9.1%)

0.717

Smoking, n (%)

8 (21.1%)

4 (36.4%)

0.298

Mild, n (%)

26 (68.4%)

7 (63.6%)

Intermediate, n (%)

10 (26.3%)

3 (27.3%)

Severe, n (%)

2 (5.3%)

1 (9.1%)

Positivity of H. pylori, n (%)

24 (63.2%)

4 (36.4%)

Activity of UC

*: P < 0.05 was the cutoff value for statistical significance.
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0.114
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